10.9.01: Third Annual UBS Warburg LLC Healthcare Conference Issue
Seven analysts and top management from one hundred eighty-seven sector firms examine the Healthcare sector in this special 673-page Third Annual UBS Warburg LLC Healthcare Conference issue from The Wall Street Transcript.

    Online subscribers to the Healthcare sector also get
    Biotechnology Issue & Bear, Stearns & Company 14th Annual Healthcare Conference Issue

  1. Outlook for Health Care Sectors - In an in-depth (2,900 words) Analyst Interview, Geoffrey Harris, Head of Global Healthcare Research & Annabel Saminy, Associate Director in the healthcare group, both at UBS Warburg, examine the outlook for the sector including biotechnology, life sciences, tools and share specific stock recommendations. Stocks mentioned in this interview include AMGN, GENZ, IDPH, GILD, IMCL, IMNX, PDLI, ICOS, IMNX, BGEN, CHIR and BMY.
  2. Medical Device & Hospital Supply Outlook - In an in-depth (3,000 words) Analyst Interview, David J. Lothson, Managing Director in the healthcare group at UBS Warburg, examines the outlook for the sector including hospital supply, medical device stocks and shares specific stock recommendations. Stocks mentioned in this interview include ABT, BAX, JNJ, BDX, MDT, EW, BSX and GDT.
  3. Small & Mid-Cap Biotechnology Stocks - In an in-depth (2,600 words) Analyst Interview, Andrew Gitkin, Executive Director at UBS Warburg, examines the outlook for the sector including small and mid-cap biotech companies, consolidation and shares specific stock recommendations. Stocks mentioned in this interview include NBIX, REGN and GSK.
  4. Medical Device Companies/Small & Mid-Cap - In an in-depth (2,600 words) Analyst Interview, Charles Olsziewski, Executive Director at UBS Warburg, examines the outlook for the sector and specific stock highlights included in this interview are Medtronic and Cooper Companies. Stocks mentioned in this interview include MDT, BSMD, STE, VAR, COO, CPTS and ENDO.
  5. Genomics & Diagnostics - In an in-depth (1,100 words) Analyst Interview, Ricky Goldwasser, Director at UBS Warburg, examines the outlook for the sector including genomics groups, diagnostics services group and shares specific stock recommendations. Stocks mentioned in this interview include MLMN, MYGN, LH, CRA, DIAN, UCOR, HGSI, DGX and SP.
  6. European Biotechnology Companies - In an in-depth (1,800 words) Analyst Interview, Karl Keegan, Head of the European Biotechnology research team in London at UBS Warburg, examines the outlook for the sector including life sciences companies, specialty pharma, biotech companies - both platforms and therapeutic and shares specific stock recommendations. Stocks mentioned in this interview include CATG, CLL, CRXL, LEON, OGSI, SRA and SHIPGY.
  7. CEO interviews (average 2,500 words). Top management of one hundred eighty-seven sector firms examine the outlook for their firm and the sector. Firms include:
    3-Dimensional Pharamceuticals, Acambis, Actelion, Agennix, Aksys, Alizyme, AltaRex, Anadys Pharmaceuticals, AnorMED, Applied Biosystems Group, Applied Molecular Evolution, ArgoMed, Argonaut Technologies, ARIAD Pharmaceuticals, ArQule, Array BioPharma, Aspect Medical Systems, AtheroGenics, AVANIR Pharmaceuticals, Avant Immunotherapeutics, Avantium Technologies, Axonyx, Beckman Coulter, Biocompatibles, BioGenex Labs, BioMedicines, Biomet, BioMicro Systems, Biomira, Bruker Daltronics, CV Therapeutics, Caliper Technologies, Cancervax, Cangene, Caprion Pharmaceuticals, CardiacAssist, CARDION, Celera Genomics, Celgene, Cellular Genomics, Cephalon, Cerus, Charles River Laboratories Int'l, Coley Pharmaceutical Group, Collateral Therapeutics, Conceptus, Corixa, Corvas International, Covance, Crucell, CryoCath Technologies, Cubist Pharmaceuticals, CuraGen, Cytogen, Cytokinetics, Dendreon, DeveloGen AG, Diversa, DUSA Pharmaceuticals, Dynacare Laboratories, Edwards Lifesciences, Entelos, Exelixis, FastTrack, Fluidigm, Gambro AB, Genaera, Genaissance Pharmaceuticals, Gene Logic, Genitope, Genmab A/S, Genome Therapeutics, Genta, Genzyme Biosurgery, Genzyme Molecular Oncology, GTx, Hemosol, Human Genome Sciences, Hyseq, ICON, ICOS, IDM, ILEX Oncology, Illumina, Immunicon, Immunomedics, Infimed Therapeutics, INGENIUM, InKine Pharmaceutical Co., Innogenetics, Inspire Pharmaceuticals, Integrative Proteomics, InterMune, Introgen Therapeutics, Intuitive Surgical, Invacare, Invitrogen, Isis Pharmaceuticals, Lexicon Genetics, Ligand Pharmaceuticals, Luminex, Masimo, MDS Proteomics, Medarex, MediChem Life Sciences, MedSource Technologies, Memory Pharmaceuticals, Metrika, Metris Therapeutics, MicroMed Technology, Miravant Medical Technologies, MitoKor, Myriad Genetics, NeoPharm, Neose Technologies, Neurobiological Technologies, Neurogen, NicOx, Novartis Pharmaceuticals Corporation – USA, Novirio Pharamceuticals, NuGenesis Technologies, Onyx Pharmaceuticals, OSI Pharmaceuticals, Osiris Therapeutics, Pain Therapeutics, Pall, Paratek Pharmaceuticals, PAREXEL International, Peptech, Peptor, Pharmacopeia, Pharmacyclics, Phase Forward, PhotoMedex, Phylos, Physiome Sciences, Phytopharm, Promega, Prometheus Labs, Qiagen, Quest Diagnostics, Quidel, RenalTech International, Rigel Pharmaceuticals, Royalty Pharma AG, Sangamo BioSciences, SangStat, Schering AG, SciClone Pharmaceuticals, Scimagix, Sepracor, SEQUENOM, Shire Pharmaceuticals Group, Signature BioScience, Songbird Hearing, SonoSite, St. Jude Medical, SuperGen, SURx, Sybron Dental Specialties, Symyx Technologies, Syrrx, Tanox, Targeted Genetics, Tecan Group AG, Telik, THERMOGENESIS, Transgenomic, TriZetto Group, Trimeris, Urologix, V.I. Technologies, Varian Medical Systems, VaxGen, Ventana Medical Systems, Versicor, ViroLogic, Visible Genetics, Wilson Greatbatch Technologies, Xencor, Xenon Genetics, X-Mine, YM Biosciences, Zarix, Zimmer Holdings, Zycos, Zymark
    8. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE